Figure 4

GFP-dynacortin localizes to the front end of cells in the presence of LY29004, a PI3 kinase inhibitor. A. Prior to LY29004 treatment, GFP-dynacortin was enriched at the leading edge (towards the needle) of the cell. B. Within 30 s of LY29004-treatment, the cells became rounded and GFP-dynacortin was uniformly distributed (0). While in 50-μM LY29004, the cell extended a pseudopod enriched in GFP-dynacortin towards the needle 20 s after bringing the needle up to the cell (+20). C. Within 3 min of LY29004-treatment, the LY29004 cells resumed their ability to move towards the needle, but without any clear polarization. GFP-dynacortin still enriched at the front of these cells. Scale bars, 10 μm. Bar in A also applies to C.